Ligand NTRK1, which expressed higher in pre-treatment non-responders, was dysregulated in C10, and IL2, a type I cytokine which can be associated with durable regression in metastatic melanoma and renal cell carcinoma [51], also was dysregulated in and only in C10 but expressed higher in on-treatment responders. Here, IL2 is linked to hereditary clear cell renal cell carcinoma.